Skip to Main Content

Paper Details

A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma.
Nat Commun
9
2023
Author NameAffiliation
Elizabeth M JaffeeThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Cancer Convergence Institute and Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine
Elizabeth M JaffeeThe Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins
Elizabeth M JaffeeThe Pancreatic Cancer Precision Medicine Center of Excellence Program at Johns Hopkins
Elizabeth M JaffeeJohns Hopkins University School of Medicine
  • 1 - 4

Datasets